本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
European Patent Office received nearly 200 000 patent applications last year, with Japanese companies and inventors filing 10.6% of the total Electrical machinery/energy, transport and computers are leading technology fields for Japanese inventions Tokyo 1st in global city ranking Sony Group is among the EPO's Top 10 applicant companies Four Japanese companies among the EPO's Top 25 applicants worldwide. MUNICH and TOKYO, March 31, 2025 /PRNewswire/ -- According to the latest Patent Index 2024, published today by the European Patent Office (EPO), Japan ranked third worldwide, following the United States and Germany. In 2024, Japanese companies and inventors filed a total of 21,062 patent applications, accounting for 10.6% of all filings at the EPO. While this represents a 2.4% decrease compared to 2023, Japan remains a powerhouse in technological advancements. Overall, the EPO received 199,264 patent applications worldwide last year, maintaining a steady level of patenting activity comparable to 2023 (199,452 applications), following three years of significant growth. "Despite political and economic uncertainties, companies and inventors from around the world filed a high number of patents last year, underlining their technological prowess and their continued investment in R&D," said EPO President António Campinos. "The EPO's patent data is a clear roadmap for industry, policy, and investment priorities – tracking global innovation trends and offering insights into European patent application activity across industries and regions." Japanese companies excel across key technological sectors Japanese companies remain leaders in multiple high-growth industries. Japan's leading field for European patent applications, electrical machinery, apparatus, energy, saw a total of 2,077 Japanese patent applications, an 8.4% increase compared to 2023. In the area of battery technologies (an important sub-field of electrical machinery), Japanese companies filed 20% more patent applications at the EPO in 2024 compared to 2023. Japan's second most important field, transport – which covers automotive, aircraft/aerospace and rail technologies, also experienced growth from Japan, with 1,357 applications, marking a 3.7% rise. The number 3 field was computer technology, with Japanese companies filing 20% more patent applications in several AI-related sub-fields.. Sony Group among the Top 10 in patent applications in Europe Four Japanese companies ranked among the top 25 patent filers at the EPO. Sony Group led the way with 1,307 applications, securing the 9th position worldwide, up from 10th in 2023. It was followed by Panasonic with 990 filings, Canon with 760 applications, while Hitachi contributed 653. Sony was no. 7 applicant overall at the EPO in computer technology. 13th in measurement and 14th in digital communication. Toyota also made significant strides, ranking no. 4 for vehicle technology (an important sub-field of transport) and second in electric propulsion (electric vehicle) technology, with a notable 12.7% increase in patent applications compared to the previous year. Japan also showed continued strength in innovation in battery technologies; in the battery-related sub-field of electrical machinery, apparatus, and energy, Japan placed three companies in the global top 10: Panasonic (4th place, 279 patents), Prime Planet Energy (8th place, 85 patents), and Toyota Motor(10th place). Tokyo 1st in city ranking: Japan's innovation hub and leading patent contributor The Tokyo metropolitan area plays a pivotal role in driving Japan's global technological presence, and it is Japan's leading prefecture with a total of 11,592 patent applications at the EPO.. Tokyo is also the second largest region worldwide for European patent filings at the EPO, behind the US state of California and ahead of Guangdong (CN), Île-de-France (FR) and Bavaria (DE). Tokyo also leads the worldwide city ranking at the EPO. Its dominance in patent filings spans a diverse range of industries, including electronics, AI, clean energy, and mobility solutions. Following Tokyo, Osaka ranks second among prefectures, with 2,979 patent applications, while Aichi takes third place with 1,447 applications, marking an impressive 21.9% growth. Unitary Patent gains in popularity in its second year The Unitary Patent system, launched in 2023, continues to gain momentum, offering innovators from around the world simpler and more accessible patent protection across 18 EU Member States with a single request to the EPO. Unitary protection was requested for 25.6% of all European patents granted by the EPO in 2024 totalling over 28,000 requests. Patentees from EPO member states had the highest uptake rate, with 36.5% of their European patents transformed into Unitary Patents, followed by those from Republic of Korea (18.9%), China (17.9%), the US (16.0%), and Japan (7.9%, up from 4.9% in 2023). Further information View the Patent Index 2024 in full Explore and customise statistics in our Statistics & Trends Centre Access Unitary Patent statistics via our dedicated dashboard Download datasets (MS Excel) in the Download data section of our statistics page Check patent trends on the go with the EPO Data Hub mobile app Read studies on innovation trends at the Observatory on Patents and Technology EPO's support for SMEs, universities, non-profit organisations and other smaller applicants Follow us on social media: X | Facebook | LinkedIn | Instagram | YouTube Official hashtag: #EPOPatentIndex About the EPOWith 6 300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 45 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching.
"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the EUSINGAPORE - Comunicae - 28 March 2025 - As part of the ongoing It's Time for European Beef campaign, led by Provacuno (the Agro-food Interprofessional Organization of the Spanish beef industry) and co-funded by the EU, European beef is set to continue its exciting journey in Singapore in 2025: with a series of visits to local production centers and retail, providing an opportunity to explore the ins and outs of Singapore's beef industry. It’s Time for European Beef This will offer a unique perspective on how local production is aligned with European standards, while also strengthening relationships between Singapore and European beef suppliers. The tour will help foster a deeper understanding of the industry, building connections and sharing knowledge and show the Singapore industry the European Production Model, one of the most rigorous in the world. To cap off the tour, there will be an exclusive tasting event at UNA at the Alkaff Mansion. The event will feature an extraordinary tasting menu designed to highlight the finest aspects of European beef from Spain. A select group of industry professionals, including key players from Singapore's beef sector, will be invited to indulge in a showcase of the beef's premium quality, versatility, and rich flavour. Renowned Michelin-starred chefs will put on a spectacular culinary display, elevating the dining experience while underscoring the exceptional qualities of European beef. This exciting event will not only celebrate the incredible flavours of European beef but also serve as a platform for engaging with Singapore's top beef industry. It's a fantastic opportunity to promote European beef's tastiness and versatility, reinforcing its reputation as a premium product that is sure to captivate the palates of the discerning Singaporean market. Another important action to be taken will be a Masterclass for culinary students. Thirty students from a local culinary academy will have the unique opportunity to train with two renowned Michelin-starred chefs from Spain. During this hands-on session, the students will learn all about the exceptional qualities of European beef, including its rich flavour, versatility, and heir cooking techniques. This masterclass promises to be an invaluable experience for the next generation of chefs, offering both education and practical experience in cooking with one of the highest quality meats in the world, beef from Europe. Hashtag: #ItstimeforEuropeanBeefThe issuer is solely responsible for the content of this announcement.
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD). The European Commission decision followed the recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in January 2025. Slenyto® is a child-appropriate prolonged release melatonin formulation that was first approved in the EU in 2018 for the treatment of insomnia in children with autism spectrum disorder (ASD) and/ or Smith-Magenis Syndrome. In 2024, the indication was extended to neurogenetic disorders (NGDs). Slenyto® is the only authorised medication for insomnia in these disorders. The adopted wording for the newly extended indication is: "Slenyto® is indicated for the treatment of insomnia: In children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient In children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient "We recognise there is significant unmet need and high demand for addressing sleep maintenance and duration as well as sleep initiation difficulties of children with ADHD, who suffer from impaired sleep. The European Commission (EC) granted marketing authorization (MA) of Slenyto® for insomnia in children with ADHD is a major move to satisfy this need." says Prof. Nava Zisapel, CEO of Neurim Pharmaceuticals. Prof. Carmen Schroder, MD, PhD, France, and Prof. Oliviero Bruni, MD, PhD, Italy, comment: " Slenyto® is a prolonged-release formulation of melatonin that delivers melatonin over the course of the night, mimicking the endogenous release profile in healthy subjects. Therefore, Slenyto® has the potential to treat the pathophysiology of insomnia in the population of children with neurodevelopmental disorders, among which ADHD, improving sleep latency, sleep continuity and total nighttime sleep duration, in particular in those who do not produce sufficient endogenous melatonin. Slenyto® has been specifically formulated for use in children and has a favorable safety profile. Subsequent improvements in child behavior (mainly due to longer uninterrupted sleep), parent satisfaction and quality of life (mainly affected by the child's behavior) are expected. The treatment will address a significant need in the medical management of many children and adolescents with ADHD". ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) Sleep impairment is a common comorbidity in ADHD, with up to 70% of children reported to experience disrupted sleep, starting at an early age. Sleep duration and the number of nighttime awakenings in children with ADHD differ from those of typically developing children from a very young age – often before formal ADHD diagnosis. Co-occurring sleep problems in children with ADHD have been shown to predict more severe core symptoms, exacerbate daytime sleepiness, and reduce quality of life in both patients and caregivers. Current practices recommend parent-directed behavioral sleep interventions as first-line treatment for pediatric insomnia in ADHD. Slenyto® is a unique pharmacological treatment for insomnia in children and adolescents with ADHD that would address not only sleep initiation but also sleep maintenance and sleep duration disorders. ABOUT SLENYTO® Slenyto® is an age-appropriate prolonged-release formulation of melatonin, a hormone involved in the regulation of the circadian clock and sleep. The mini-tablet's innovative formulation was specifically designed to facilitate ease of swallowing without resistance in pediatric ASD, NGD and ADHD populations, in response to the unmet need in the field of paediatric insomnia. Slenyto® delivers melatonin over the night to mimic the endogenous melatonin release profile in healthy subjects. In Phase III study in ASD and SMS children and adolescents, with and without ADHD, Slenyto® improved sleep latency, sleep continuity, and total nighttime sleep duration. The positive effect on sleep maintenance and duration was associated with an improvement in externalizing behavior, which correlated with improvement in parents' well-being. Analysis of Slenyto effect on the primary endpoint, total sleep time, demonstrated the same level of improvement in participants with and without ADHD comorbidity. The mechanism of action of Slenyto® on sleep latency, sleep maintenance and total sleep time is independent of the background disorder. Therefore, any patient with a neurodevelopmental disorder with sleep disturbances associated with aberrant diurnal melatonin secretion patterns and/or insufficient nighttime melatonin secretion will benefit from Slenyto®. ABOUT NEURIM PHARMACEUTICALS Neurim Pharmaceuticals Ltd. (www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug, CIRCADIN®, is approved for patients over the age of 55 who are suffering from insomnia and is commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. Contact: Guy Manor, VP Commercial Operations, guym@neurim.com
BELGRADE, Serbia, March 24, 2025 /PRNewswire/ -- From March 17th to 21st, the China Council for the Promotion of International Trade (CCPIT) led a delegation of Chinese entrepreneurs on a visit to Italy and Serbia. During the tour, CCPIT hosted the Economic and Trade Cooperation Forum in concert with the Promotion Conference for the 3rd China International Supply Chain Expo (the Expo) in Milan, Italy, and Belgrade, Serbia. The China-Italy Economic and Trade Forum and the Third China International Supply Chain Expo Promotion Event Was Held in Milan. Ren noted that this year commemorates the 50th anniversary of diplomatic ties between China and the European Union. Over the past half-century, considerable progress has been made in various domains of pragmatic cooperation between the two regions. CCPIT is committed to working with all stakeholders to enhance industrial and supply chain collaborations within the international business community and to share opportunities for growth and development with European nations. The council is eager to advance high-level openness to ensure a favorable business environment for the private sector. In addition, CCPIT seeks to strengthen bilateral relations through balanced and reciprocal multilateralism and to advocate for the liberalization and facilitation of trade and investment. The council aims to intensify collaboration in traditional sectors between the two regions while exploring new areas such as renewable energy, the digital economy, and equipment manufacturing. "European firms are invited to participate in the upcoming Expo, utilizing the event as a forum to bolster industrial and supply chain exchanges and establish safer, more robust partnerships. As principal global economies, China and the EU are solidifying their cooperative foundations," said Ren. "which not only stabilizes bilateral relations and strengthens resilience against external risks but also provides new momentum into the global economic resurgence. This pledge underscores the commitment of both China and European nations to nurture an open world economy." Several prominent guests delivered addresses at the event, including Mario Boselli, President of the Italy China Council Foundation, David Doninotti, Secretary General of the Italian Association of Foreign Trade, Liu Kan, Consul General of China in Milan, Marko Čadež, President of the Chamber of Commerce and Industry of Serbia, Adrijana Mesarović, Minister of Economy of Serbia and Li Ming, Ambassador of China to Serbia. The event drew over 400 delegates from Italian and Serbian trade and investment promotion organizations, business associations, and firms. During the gathering, the China International Exhibition Center Group signed several cooperation agreements with various organizations and businesses.
SUZHOU, China, March 24, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. The application seeks approval for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent or sequential platinum-based chemoradiotherapy (CRT). This marks CStone's second regulatory submission for sugemalimab to the EMA, following its initial approval in Europe for metastatic squamous and non-squamous NSCLC in 2024. If this new indication is approved, sugemalimab would address a critical unmet need in stage III NSCLC, where only one PD-L1 antibody is currently approved in Europe. The drug's dual utility in stage III and IV NSCLC could solidify its role as a cornerstone immunotherapy in lung cancer. The submission is supported by data from the GEMSTONE-301 Phase III trial, a multicenter, randomized, double-blind study evaluating sugemalimab as consolidation therapy in patients with unresectable stage III NSCLC post-CRT. Results published in The Lancet Oncology demonstrated: 36% reduction in risk of disease progression or death, significantly improved progression-free survival (PFS). 56% reduction in risk of death, with a strong positive trend toward overall survival (OS) benefit. Consistent clinical benefits across subgroups, regardless of prior CRT modality (concurrent or sequential). Favorable safety profile, no new safety signals identified. Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, commented: "Following sugemalimab's approval in Europe for stage IV NSCLC, we are working closely with EMA to expand its indications in earlier stage lung cancer and other malignancies. With its demonstrated outstanding efficacy and safety profile, sugemalimab is poised to address critical unmet needs for stage III NSCLC patients. We remain steadfast in expanding global access through strategic partnerships and collaborations with regulatory authorities, ensuring this innovative therapy reaches patients worldwide." About Sugemalimab The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs. The European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations. The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications: In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and metastatic squamous NSCLC; For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy; For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma; In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression CPS ≥5. About CStone CStone Pharmaceuticals (HKEX: 2616), founded in late 2015, is an innovation-driven biopharmaceutical company focused on advancing cutting-edge oncology therapies. Committed to addressing unmet medical needs globally, the company has achieved remarkable milestones since its inception, including the successful launch of four novel therapeutics and securing 16 regulatory approvals across nine indications. CStone's robust pipeline features 16 high-potential candidates, including first-in-class and best-in-class assets such as antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies, and precision medicines. The company further distinguishes itself through a seasoned leadership team with comprehensive expertise in drug development—from preclinical research and clinical trials to manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.IR contact: ir@cstonepharma.com PR contact: pr@cstonepharma.com Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.
HONG KONG SAR - Media OutReach Newswire - 17 March 2025 - Mr Albert Wong, CEO of Hong Kong Science and Technology Parks Corporation (HKSTP), led a delegation on a highly successful European Innovation Mixer tour in March, engaging with over 1,000 students and innovation and technology (I&T) talents, encouraging them to pursue opportunities in Hong Kong. The delegation also secured over 1,000 business collaboration opportunities, further strengthening Hong Kong's I&T ecosystem. The delegation from HKSTP visit multiple universities ranked among the world’s top 10 in the UK and hold multiple sharing sessions on campus to engage in face-to-face interactions with local students. As part of its European tour, HKSTP together with the Hong Kong Trade Development Council (HKTDC), led 24 I&T companies to the Mobile World Congress (MWC) 2025 in Barcelona, achieving remarkable results. The Hong Kong Pavilion welcomed over 7,500 visitors, attracting representatives from global brands such as AT&T, Deutsche Telekom, Orange, T-Mobile, Verizon and Vodafone, and securing 1,000+ business collaboration opportunities. HKSTP also signed a cooperation agreement with 22@Network Barcelona to bolster cross-regional exchanges and jointly promote the sustainable development of innovative technologies. The delegation also visited multiple universities ranked among the world's top 10 in the UK, including Imperial College London, the University of Oxford, the University of Cambridge, and the University College London. They met with representatives from academic departments, research institutes, and innovation and entrepreneurship centres to explore various collaboration opportunities in talent development and startup incubation. The delegation hosted multiple sharing sessions on campuses, engaging with over 300 local students face-to-face and introducing internship and career opportunities at Hong Kong Science Park. They actively encouraged Hong Kong students pursuing studies in the UK to return to Hong Kong for work or entrepreneurship, collectively contributing to the thriving growth of Hong Kong's I&T ecosystem. HKSTP works closely with the government, industry, academia, and research sectors. In London, HKSTP co-hosted a seminar with the Hong Kong Economic and Trade Office in London (HKETO-London), Invest Hong Kong (InvestHK), and the Office for Attracting Strategic Enterprises (OASES). The event attracted interest from the local business community, academia, and I&T sector, with nearly 100 attendees focusing on Hong Kong's potential investment and collaboration opportunities. The seminar featured guest speakers delivering keynote speeches on Hong Kong's I&T development prospects, highlighting the city's dynamic I&T ecosystem. During his speech at the seminar, Mr Albert Wong, CEO of HKSTP, said: "As a growing engine situated at an international I&T hub in Asia, the HKSTP understands that nurturing next-generation I&T talent is as important as any R&D project, if not more. We're currently an ecosystem that over 2,200 tech companies from 26 countries and regions call home, offering comprehensive support to more than 15,000 research and development professionals - a network we're looking overseas to extend, and a number we're eager to invest in for a sustainable future." While continuing to support park companies in recruiting overseas talent, HKSTP will soon launch a new talent programme designed to attract Hong Kong students and research professionals abroad to pursue careers in the city. The programme will provide eligible park companies with targeted salary subsidies and accommodation support for returning professionals, incentivising them to leverage the immense opportunities within Hong Kong's thriving I&T ecosystem. Together, these efforts will advance Hong Kong's rise as a leading global I&T hub. Hashtag: #HKSTPThe issuer is solely responsible for the content of this announcement.Hong Kong Science and Technology Parks CorporationMore information about HKSTP is available at www.hkstp.org.
#european
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
